2
RESEARCH METHODOLOGY
37
5
MARKET OVERVIEW
Emerging economies and POC diagnostics drive market growth amid regulatory and reimbursement challenges.
60
5.2.1.1
Increasing prevalence of infectious diseases and cancer
5.2.1.2
Increasing focus on decentralized diagnostics and subsequent rise in R&D funding
5.2.1.3
Growing awareness associated with early disease diagnosis
5.2.1.4
Increasing use of POC diagnostic tests
5.2.2.1
Unfavorable reimbursements
5.2.2.2
High capital investments and low cost-benefit ratio
5.2.3.1
Growth opportunities in emerging economies
5.2.4.1
Stringent regulatory guidelines that impact product commercialization
5.2.4.2
Introduction of alternative technologies
5.3.1
AVERAGE PRICE TREND OF POINT OF CARE MOLECULAR DIAGNOSTIC PRODUCTS, 2023−2025
5.3.2
AVERAGE PRICE TREND OF POINT OF CARE MOLECULAR DIAGNOSTIC ASSAYS & KITS, BY KEY PLAYER, 2023−2025
5.3.3
AVERAGE SELLING PRICE TREND OF POINT OF CARE MOLECULAR DIAGNOSTIC PRODUCTS, BY REGION, 2023−2025
5.4.1
LIST OF KEY PATENTS
5.6
SUPPLY CHAIN ANALYSIS
5.7.1
TRADE ANALYSIS FOR DIAGNOSTIC & LABORATORY REAGENTS
5.7.2
IMPORT DATA (HS CODE 3822)
5.7.3
EXPORT DATA (HS CODE 3822)
5.8.1
POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: ROLE IN ECOSYSTEM
5.9
PORTER’S FIVE FORCES ANALYSIS
5.9.1
THREAT OF NEW ENTRANTS
5.9.2
BARGAINING POWER OF SUPPLIERS
5.9.3
THREAT OF SUBSTITUTES
5.9.4
BARGAINING POWER OF BUYERS
5.9.5
INTENSITY OF COMPETITIVE RIVALRY
5.10
REGULATORY LANDSCAPE
5.10.1
REGULATORY FRAMEWORK
5.10.2
REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.11.2
COMPLEMENTARY TECHNOLOGIES
5.11.2.1
INAAT (Isolated Nucleic Acid Amplification Technology)
5.11.3
ADJACENT TECHNOLOGIES
5.11.3.1
CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats)
5.12
KEY CONFERENCES & EVENTS, 2025–2026
5.13
TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.14
KEY STAKEHOLDERS & BUYING CRITERIA
5.14.1
KEY STAKEHOLDERS IN BUYING PROCESS
5.15
INVESTMENT & FUNDING SCENARIO
5.16.1
CASE STUDY 1: RAPID POINT OF CARE PCR TESTING STREAMLINES EMERGENCY CARE FOR HOSPITAL IN GERMANY
5.16.2
CASE STUDY 2: IMPLEMENTATION OF RAPID PCR TESTING TO IMPROVE NOROVIRUS DIAGNOSIS & BED MANAGEMENT
5.16.3
CASE STUDY 3: USING MOLECULAR DIAGNOSTICS TO IDENTIFY ATYPICAL RESPIRATORY INFECTION
5.17
IMPACT OF AI/GENERATIVE AI IN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET
5.17.2
MARKET POTENTIAL OF AI
5.17.4
IMPLEMENTATION OF AI, BY KEY COMPANY & USE CASE
5.17.5
FUTURE OF AI IN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET
5.18
TRUMP TARIFF IMPACT ON POINT OF CARE MOLECULAR DIAGNOSTICS MARKET
5.18.3
PRICE IMPACT ANALYSIS
5.18.4
IMPACT ON COUNTRY/REGION
5.18.5
IMPACT ON END-USE INDUSTRIES
5.18.5.1
Physicians’ Offices/Clinics
5.18.5.3
Research Institutes
6
POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 22 Data Tables
99
6.2.1
RECURRENT PURCHASE TO PROPEL MARKET
6.3
INSTRUMENTS & ANALYZERS
6.3.1
INCREASING ADOPTION OF ADVANCED POC TECHNOLOGIES TO DRIVE MARKET
6.4.1
UTILIZATION OF SOLUTIONS FOR ENHANCED USER EXPERIENCE TO SUPPORT MARKET GROWTH
7
POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 21 Data Tables
111
7.2.1
HIGH SENSITIVITY AND SPECIFICITY TO BOOST DEMAND
7.3.1
COST-BENEFITS AND RAPID AMPLIFICATION ABILITIES TO PROPEL MARKET
8
POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 22 Data Tables
122
8.2.1
ABILITY TO SUPPORT RAPID DETECTION FOR SEVERAL DISEASES TO PROPEL MARKET
8.3.1
NON-INVASIVE NATURE AND DETECTION OF LOW BIOMARKER CONCENTRATION TO BOOST DEMAND
9
POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 49 Data Tables
133
9.2.1
RISING INCIDENCE OF INFLUENZA AND RSV TO DRIVE MARKET
9.3
SEXUALLY TRANSMITTED DISEASES
9.3.1
RISING PREVALENCE OF HPV AND HIV TO DRIVE MARKET
9.4
HOSPITAL-ACQUIRED INFECTIONS
9.4.1
GROWING FOCUS ON TARGETED CLINICAL THERAPY FOR REDUCTION IN HAIS TO FUEL MARKET
9.5.1
INCREASING PREFERENCE FOR ONCOLOGY THERAPEUTICS TO DRIVE MARKET
9.6.1
INCREASING PREVALENCE AMONG HIGH-RISK SUBGROUP POPULATIONS TO PROPEL MARKET
9.7
GASTROINTESTINAL DISORDERS
9.7.1
RISING INCIDENCE OF IBS TO SUPPORT MARKET GROWTH
10
POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 26 Data Tables
158
10.2.1
CAPABILITY TO PURCHASE ADVANCED DIAGNOSTIC EQUIPMENT AND ABILITY TO SUPPORT HIGH PATIENT FOOTFALL TO PROPEL MARKET
10.2.1.3
Meningoencephalitis
10.3
PHYSICIANS’ OFFICES/CLINICS
10.3.1
RAPID RESULTS AND INDIVIDUALIZED CARE TO FUEL MARKET
10.4.1
INCREASING FOCUS ON GENOMICS & PROTEOMICS RESEARCH TO BOOST DEMAND
11
POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY REGION
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 126 Data Tables
173
11.2.1
NORTH AMERICA: MACROECONOMIC OUTLOOK
11.2.2.1
High healthcare expenditure for advanced molecular diagnostic technologies to drive market
11.2.3.1
Favorable government initiatives for early disease diagnosis awareness to fuel market
11.3.1
EUROPE: MACROECONOMIC OUTLOOK
11.3.2.1
Universal healthcare coverage and favorable growth for decentralized care settings to fuel market
11.3.3.1
Rising prevalence of STIs to boost demand
11.3.4.1
High disease burden of infectious diseases and cancer to drive market
11.3.5.1
Rising demand for high-precision diagnostic tools to support market growth
11.3.6.1
Rising incidence of respiratory illnesses and HIV to boost demand
11.4.1
ASIA PACIFIC: MACROECONOMIC OUTLOOK
11.4.2.1
Increasing incidence of influenza and epidemics to propel market
11.4.3.1
Growing access to advanced & affordable healthcare services to fuel market
11.4.4.1
Expanding healthcare access and increasing prevalence of HIV to propel market
11.4.5
REST OF ASIA PACIFIC
11.5.1
LATIN AMERICA: MACROECONOMIC OUTLOOK
11.5.2.1
High incidence of hepatitis to support market uptake
11.5.3.1
Rising cases of TB and HAIs to fuel market
11.5.4
REST OF LATIN AMERICA
11.6
MIDDLE EAST & AFRICA
11.6.1
MIDDLE EAST & AFRICA: MACROECONOMIC OUTLOOK
11.6.2
KINGDOM OF SAUDI ARABIA (KSA)
11.6.2.1
Improvements in healthcare infrastructure to drive market
11.6.3
UNITED ARAB EMIRATES (UAE)
11.6.3.1
Rising technological advancements in molecular diagnostics to fuel market
11.6.4
REST OF MIDDLE EAST & AFRICA
12
COMPETITIVE LANDSCAPE
Discover strategic moves and market positions of leading and emerging players in molecular diagnostics.
246
12.2
KEY PLAYER STRATEGIES/RIGHT TO WIN
12.2.1
OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET
12.3
REVENUE SHARE ANALYSIS, 2022−2024
12.4
MARKET SHARE ANALYSIS, 2024
12.5
COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
12.5.5
COMPANY FOOTPRINT: KEY PLAYERS, 2024
12.5.5.1
Company footprint
12.5.5.2
Region footprint
12.5.5.3
Product & service footprint
12.5.5.4
Technology footprint
12.5.5.5
Application footprint
12.6
COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
12.6.1
PROGRESSIVE COMPANIES
12.6.2
RESPONSIVE COMPANIES
12.6.5
COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
12.6.5.1
Detailed list of key startups/SMEs
12.6.5.2
Competitive benchmarking of key emerging players/startups (1/2)
12.6.5.3
Competitive benchmarking of key startups/SMEs (2/2)
12.7
COMPANY VALUATION & FINANCIAL METRICS
12.8
BRAND/PRODUCT COMPARISON
12.8.1
BRAND/PRODUCT COMPARATIVE ANALYSIS
12.9
COMPETITIVE SCENARIO
12.9.1
PRODUCT/SERVICE LAUNCHES & APPROVALS
13
COMPANY PROFILES
In-depth Company Profiles of Leading Market Players with detailed Business Overview, Product and Service Portfolio, Recent Developments, and Unique Analyst Perspective (MnM View)
265
13.1.1
DANAHER CORPORATION
13.1.1.1
Business overview
13.1.1.2
Products/Services offered
13.1.1.3
Recent developments
13.1.3
F. HOFFMANN-LA ROCHE LTD.
13.1.6
QUIDELORTHO CORPORATION
13.1.7
CO-DIAGNOSTICS, INC.
13.1.9
SD BIOSENSOR, INC.
13.2.2
MOLBIO DIAGNOSTICS LIMITED
13.2.5
VISBY MEDICAL, INC.
13.2.6
QUANTUMDX GROUP LTD.
13.2.8
LABSYSTEMS DIAGNOSTICS OY
13.2.9
AKONNI BIOSYSTEMS, INC.
13.2.10
UBIQUITOME LIMITED
13.2.11
CREDO DIAGNOSTICS BIOMEDICAL PTE. LTD.
13.2.15
HUWEL LIFESCIENCES
14.2
KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.3
CUSTOMIZATION OPTIONS
TABLE 1
POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: INCLUSIONS & EXCLUSIONS
TABLE 2
POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: KEY DATA FROM PRIMARY SOURCES
TABLE 3
POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: RISK ASSESSMENT ANALYSIS
TABLE 4
REGIONAL HIV DATA, 2024
TABLE 5
AVERAGE SELLING PRICING TREND OF POINT OF CARE MOLECULAR DIAGNOSTIC PRODUCTS, 2023–2025
TABLE 6
AVERAGE SELLING PRICE TREND OF POINT OF CARE MOLECULAR DIAGNOSTIC ASSAYS & KITS, BY KEY PLAYER, 2023–2025
TABLE 7
AVERAGE SELLING PRICE TREND OF POINT OF CARE MOLECULAR DIAGNOSTIC PRODUCTS, BY REGION, 2023–2025
TABLE 8
POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: LIST OF MAJOR PATENTS
TABLE 9
IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS (HS CODE 3822), BY COUNTRY, 2020–2024 (USD MILLION)
TABLE 10
EXPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS (HS CODE 3822), BY COUNTRY, 2020–2024 (USD MILLION)
TABLE 11
POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: ROLE IN ECOSYSTEM
TABLE 12
POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS
TABLE 13
CLASSIFICATION OF IVD DEVICES IN EUROPE
TABLE 14
TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS IN JAPAN
TABLE 17
ASIA PACIFIC: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 20
POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: DETAILED LIST OF KEY CONFERENCES & EVENTS, JANUARY 2025–DECEMBER 2026
TABLE 21
INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF POINT OF CARE MOLECULAR DIAGNOSTIC PRODUCTS (%)
TABLE 22
KEY BUYING CRITERIA FOR POINT OF CARE MOLECULAR DIAGNOSTIC PRODUCTS
TABLE 23
IMPLEMENTATION OF AI, BY KEY COMPANY & USE CASE
TABLE 24
US-ADJUSTED RECIPROCAL TARIFF RATES
TABLE 25
POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
TABLE 26
KEY ASSAYS & KITS CURRENTLY AVAILABLE
TABLE 27
POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR ASSAYS & KITS, BY REGION, 2023–2030 (USD MILLION)
TABLE 28
NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR ASSAYS & KITS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 29
EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR ASSAYS & KITS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 30
ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR ASSAYS & KITS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 31
LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR ASSAYS & KITS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 32
MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR ASSAYS & KITS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 33
KEY INSTRUMENTS & ANALYZERS CURRENTLY AVAILABLE
TABLE 34
POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR INSTRUMENTS & ANALYZERS, BY REGION, 2023–2030 (USD MILLION)
TABLE 35
NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR INSTRUMENTS & ANALYZERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 36
EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR INSTRUMENTS & ANALYZERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 37
ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR INSTRUMENTS & ANALYZERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 38
LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR INSTRUMENTS & ANALYZERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 39
MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR INSTRUMENTS & ANALYZERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 40
KEY SOFTWARE & SERVICES CURRENTLY AVAILABLE
TABLE 41
POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY REGION, 2023–2030 (USD MILLION)
TABLE 42
NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 43
EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 44
ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 45
LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 46
MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 47
POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 48
KEY RT-PCR-BASED PRODUCTS CURRENTLY AVAILABLE
TABLE 49
POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR RT-PCR, BY REGION, 2023–2030 (USD MILLION)
TABLE 50
NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR RT-PCR, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 51
EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR RT-PCR, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 52
ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR RT-PCR, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 53
LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR RT-PCR, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 54
MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR RT-PCR, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 55
KEY INAAT-BASED PRODUCTS CURRENTLY AVAILABLE
TABLE 56
POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR INAAT, BY REGION, 2023–2030 (USD MILLION)
TABLE 57
NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR INAAT, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 58
EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR INAAT, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 59
ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR INAAT, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 60
LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR INAAT, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 61
MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR INAAT, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 62
POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2023–2030 (USD MILLION)
TABLE 63
NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 64
EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 65
ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 66
LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 67
MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 68
POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE,2023–2030 (USD MILLION)
TABLE 69
KEY BLOOD SAMPLE TYPE-BASED PRODUCTS CURRENTLY AVAILABLE
TABLE 70
POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY REGION, 2023–2030 (USD MILLION)
TABLE 71
NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 72
EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 73
ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 74
LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 75
MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 76
KEY URINE SAMPLE-BASED PRODUCTS CURRENTLY AVAILABLE
TABLE 77
POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR URINE SAMPLES, BY REGION, 2023–2030 (USD MILLION)
TABLE 78
NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR URINE SAMPLES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 79
EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR URINE SAMPLES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 80
ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR URINE SAMPLES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 81
LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR URINE SAMPLES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 82
MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR URINE SAMPLES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 83
KEY OTHER SAMPLE TYPE-BASED PRODUCTS CURRENTLY AVAILABLE
TABLE 84
POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY REGION, 2023–2030 (USD MILLION)
TABLE 85
NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 86
EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 87
ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 88
LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 89
MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 90
POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 91
KEY POC MOLECULAR DIAGNOSTIC PRODUCTS FOR RESPIRATORY DISEASES CURRENTLY AVAILABLE
TABLE 92
POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY DISEASES, BY REGION, 2023–2030 (USD MILLION)
TABLE 93
NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 94
EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 95
ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 96
LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 97
MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 98
NUMBER OF NEWLY DIAGNOSED TUBERCULOSIS (TB) CASES, 2023–2030 (IN MILLIONS)
TABLE 99
KEY POC MOLECULAR DIAGNOSTIC PRODUCTS FOR SEXUALLY TRANSMITTED DISEASES CURRENTLY AVAILABLE
TABLE 100
POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY REGION, 2023–2030 (USD MILLION)
TABLE 101
NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 102
EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 103
ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 104
LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 105
MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 106
POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY REGION, 2023–2030 (USD MILLION)
TABLE 107
NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 108
EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 109
ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 110
LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 111
MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 112
POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR CANCER, BY REGION, 2023–2030 (USD MILLION)
TABLE 113
NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR CANCER, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 114
EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR CANCER, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 115
ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR CANCER, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 116
LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR CANCER, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 117
MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR CANCER, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 118
KEY POC MOLECULAR DIAGNOSTIC PRODUCTS FOR HEPATITIS CURRENTLY AVAILABLE
TABLE 119
POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY REGION, 2023–2030 (USD MILLION)
TABLE 120
NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 121
EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 122
ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 123
LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 124
MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 125
KEY POC MOLECULAR DIAGNOSTIC PRODUCTS FOR GASTROINTESTINAL DISORDERS CURRENTLY AVAILABLE
TABLE 126
POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR GASTROINTESTINAL DISORDERS, BY REGION, 2023–2030 (USD MILLION)
TABLE 127
NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR GASTROINTESTINAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 128
EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR GASTROINTESTINAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 129
ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR GASTROINTESTINAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 130
LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR GASTROINTESTINAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 131
MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR GASTROINTESTINAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 132
KEY POC MOLECULAR DIAGNOSTIC PRODUCTS FOR OTHER APPLICATIONS CURRENTLY AVAILABLE
TABLE 133
POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY REGION, 2023–2030 (USD MILLION)
TABLE 134
NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOROTHER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 135
EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 136
ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 137
LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 138
MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 139
POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 140
POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR HOSPITALS, BY REGION, 2023–2030 (USD MILLION)
TABLE 141
POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR HOSPITALS, BY DISEASE TYPE, 2023–2030 (USD MILLION)
TABLE 142
NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR HOSPITALS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 143
EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR HOSPITALS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 144
ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR HOSPITALS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 145
LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR HOSPITALS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 146
MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR HOSPITALS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 147
POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR PHYSICIANS’ OFFICES/CLINICS, BY REGION, 2023–2030 (USD MILLION)
TABLE 148
NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR PHYSICIANS’ OFFICES/CLINICS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 149
EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR PHYSICIANS’ OFFICES/CLINICS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 150
ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR PHYSICIANS’ OFFICES/CLINICS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 151
LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR PHYSICIANS’ OFFICES/CLINICS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 152
MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR PHYSICIANS’ OFFICES/CLINICS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 153
POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR RESEARCH INSTITUTES, BY REGION, 2023–2030 (USD MILLION)
TABLE 154
NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 155
EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 156
ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 157
LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 158
MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 159
POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2023–2030 (USD MILLION)
TABLE 160
NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 161
EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 162
ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 163
LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 164
MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 165
POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 166
NORTH AMERICA: MACROECONOMIC INDICATORS
TABLE 167
NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 168
NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
TABLE 169
NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 170
NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
TABLE 171
NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 172
NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 173
US: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
TABLE 174
US: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 175
US: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
TABLE 176
US: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 177
US: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 178
CANADA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
TABLE 179
CANADA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 180
CANADA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
TABLE 181
CANADA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 182
CANADA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 183
EUROPE: MACROECONOMIC INDICATORS
TABLE 184
EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 185
EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
TABLE 186
EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 187
EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
TABLE 188
EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 189
EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 190
GERMANY: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
TABLE 191
GERMANY: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 192
GERMANY: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
TABLE 193
GERMANY: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 194
GERMANY: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 195
UK: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
TABLE 196
UK: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 197
UK: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
TABLE 198
UK: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 199
UK: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 200
FRANCE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
TABLE 201
FRANCE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 202
FRANCE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
TABLE 203
FRANCE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 204
FRANCE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 205
ITALY: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
TABLE 206
ITALY: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 207
ITALY: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
TABLE 208
ITALY: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 209
ITALY: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 210
SPAIN: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
TABLE 211
SPAIN: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 212
SPAIN: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
TABLE 213
SPAIN: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 214
SPAIN: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 215
REST OF EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
TABLE 216
REST OF EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 217
REST OF EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
TABLE 218
REST OF EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 219
REST OF EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 220
ASIA PACIFIC: MACROECONOMIC INDICATORS
TABLE 221
ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 222
ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
TABLE 223
ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 224
ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
TABLE 225
ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 226
ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 227
CHINA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
TABLE 228
CHINA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 229
CHINA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
TABLE 230
CHINA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 231
CHINA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 232
JAPAN: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
TABLE 233
JAPAN: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 234
JAPAN: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
TABLE 235
JAPAN: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 236
JAPAN: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 237
INDIA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
TABLE 238
INDIA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 239
INDIA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
TABLE 240
INDIA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 241
INDIA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 242
REST OF ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
TABLE 243
REST OF ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 244
REST OF ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
TABLE 245
REST OF ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 246
REST OF ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 247
LATIN AMERICA: MACROECONOMIC INDICATORS
TABLE 248
LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 249
LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
TABLE 250
LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 251
LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
TABLE 252
LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 253
LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 254
BRAZIL: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
TABLE 255
BRAZIL: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 256
BRAZIL: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
TABLE 257
BRAZIL: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 258
BRAZIL: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 259
MEXICO: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
TABLE 260
MEXICO: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 261
MEXICO: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
TABLE 262
MEXICO: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 263
MEXICO: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 264
REST OF LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
TABLE 265
REST OF LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 266
REST OF LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
TABLE 267
REST OF LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 268
REST OF LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 269
MIDDLE EAST & AFRICA: MACROECONOMIC INDICATORS
TABLE 270
MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 271
MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
TABLE 272
MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 273
MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
TABLE 274
MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 275
MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 276
KINGDOM OF SAUDI ARABIA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
TABLE 277
KINGDOM OF SAUDI ARABIA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 278
KINGDOM OF SAUDI ARABIA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
TABLE 279
KINGDOM OF SAUDI ARABIA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 280
KINGDOM OF SAUDI ARABIA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 281
UNITED ARAB EMIRATES: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
TABLE 282
UNITED ARAB EMIRATES: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 283
UNITED ARAB EMIRATES: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
TABLE 284
UNITED ARAB EMIRATES: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 285
UNITED ARAB EMIRATES: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 286
REST OF MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
TABLE 287
REST OF MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 288
REST OF MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
TABLE 289
REST OF MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 290
REST OF MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 291
OVERVIEW OF STRATEGIES DEPLOYED BY KEY COMPANIES IN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, JANUARY 2021−JULY 2025
TABLE 292
POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: DEGREE OF COMPETITION
TABLE 293
POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: REGION FOOTPRINT
TABLE 294
POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: PRODUCT & SERVICE FOOTPRINT
TABLE 295
POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: TECHNOLOGY FOOTPRINT
TABLE 296
POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: APPLICATION FOOTPRINT
TABLE 297
POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: DETAILED LIST OF KEY STARTUPS/SMES
TABLE 298
POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS (1/2)
TABLE 299
POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES (2/2)
TABLE 300
POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021–JULY 2025
TABLE 301
POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: DEALS, JANUARY 2021–JULY 2025
TABLE 302
POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: EXPANSIONS, JANUARY 2021–JULY 2025
TABLE 303
DANAHER CORPORATION: COMPANY OVERVIEW
TABLE 304
DANAHER CORPORATION: PRODUCTS/SERVICES OFFERED
TABLE 305
DANAHER CORPORATION: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021–JULY 2025
TABLE 306
DANAHER CORPORATION: DEALS, JANUARY 2021–JULY 2025
TABLE 307
DANAHER CORPORATION: EXPANSIONS, JANUARY 2021–JULY 2025
TABLE 308
BIOMÉRIEUX: COMPANY OVERVIEW
TABLE 309
BIOMÉRIEUX: PRODUCTS/SERVICES OFFERED
TABLE 310
BIOMÉRIEUX: PRODUCT/SERVICE APPROVALS, JANUARY 2021–JULY 2025
TABLE 311
BIOMÉRIEUX: DEALS, JANUARY 2021–JULY 2025
TABLE 312
F. HOFFMANN-LA ROCHE LTD: COMPANY OVERVIEW
TABLE 313
F. HOFFMANN-LA ROCHE LTD.: PRODUCTS/SERVICES OFFERED
TABLE 314
F. HOFFMANN-LA ROCHE LTD.: PRODUCTS/SERVICES LAUNCHES & APPROVALS, JANUARY 2021–JULY 2025
TABLE 315
F. HOFFMANN-LA ROCHE LTD.: DEALS, JANUARY 2021–JULY 2025
TABLE 316
F. HOFFMANN-LA ROCHE LTD.: EXPANSIONS, JANUARY 2021–JULY 2025
TABLE 317
ABBOTT: COMPANY OVERVIEW
TABLE 318
ABBOTT PRODUCTS/SERVICES OFFERED
TABLE 319
ABBOTT: DEALS, JANUARY 2021–JULY 2025
TABLE 320
QIAGEN N.V.: COMPANY OVERVIEW
TABLE 321
QIAGEN N.V.: PRODUCTS/SERVICES OFFERED
TABLE 322
QIAGEN N.V.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–JULY 2025
TABLE 323
QIAGEN N.V.: DEALS, JANUARY 2021–JULY 2025
TABLE 324
QIAGEN N.V.: EXPANSIONS, JANUARY 2021–JULY 2025
TABLE 325
QUIDELORTHO CORPORATION: COMPANY OVERVIEW
TABLE 326
QUIDELORTHO CORPORATION: PRODUCTS/SERVICES OFFERED
TABLE 327
QUIDELORTHO CORPORATION: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021–JULY 2025
TABLE 328
QUIDELORTHO CORPORATION: DEALS, JANUARY 2021–JULY 2025
TABLE 329
QUIDELORTHO CORPORATION: EXPANSIONS, JANUARY 2021–JULY 2025
TABLE 330
CO-DIAGNOSTICS, INC.: COMPANY OVERVIEW
TABLE 331
CO-DIAGNOSTICS, INC.: PRODUCTS/SERVICES OFFERED
TABLE 332
CO-DIAGNOSTICS, INC.: DEALS, JANUARY 2021–JULY 2025
TABLE 333
CO-DIAGNOSTICS, INC.: EXPANSIONS, JANUARY 2021–JULY 2025
TABLE 334
BIOCARTIS: COMPANY OVERVIEW
TABLE 335
BIOCARTIS: PRODUCTS/SERVICES OFFERED
TABLE 336
BIOCARTIS: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021–JULY 2025
TABLE 337
BIOCARTIS: DEALS, JANUARY 2021–JULY 2025
TABLE 338
SD BIOSENSOR, INC.: BUSINESS OVERVIEW
TABLE 339
SD BIOSENSOR, INC.: PRODUCTS/SERVICES OFFERED
TABLE 340
SD BIOSENSOR, INC.: PRODUCT/SERVICE LAUNCHES, JANUARY 2021–JULY 2025
TABLE 341
SD BIOSENSOR, INC.: DEALS, JANUARY 2021–JULY 2025
TABLE 342
SD BIOSENSOR, INC.: OTHER DEVELOPMENTS, JANUARY 2021–JULY 2025
TABLE 343
GENEDRIVE PLC: COMPANY OVERVIEW
TABLE 344
GENEDRIVE PLC: PRODUCTS/SERVICES OFFERED
TABLE 345
BINX HEALTH, INC.: COMPANY OVERVIEW
TABLE 346
MOLBIO DIAGNOSTICS LIMITED: COMPANY OVERVIEW
TABLE 347
OPGEN, INC.: COMPANY OVERVIEW
TABLE 348
GENOMADIX: COMPANY OVERVIEW
TABLE 349
VISBY MEDICAL, INC.: COMPANY OVERVIEW
TABLE 350
QUANTUMDX GROUP LTD.: COMPANY OVERVIEW
TABLE 351
DETECTACHEM: COMPANY OVERVIEW
TABLE 352
LABSYSTEMS DIAGNOSTICS OY: COMPANY OVERVIEW
TABLE 353
AKONNI BIOSYSTEMS, INC.: COMPANY OVERVIEW
TABLE 354
UBIQUITOME LIMITED: COMPANY OVERVIEW
TABLE 355
CREDO DIAGNOSTICS BIOMEDICAL PTE. LTD.: COMPANY OVERVIEW
TABLE 356
NUCLEIN, LLC: COMPANY OVERVIEW
TABLE 357
GENES2ME: COMPANY OVERVIEW
TABLE 358
AXXIN: COMPANY OVERVIEW
TABLE 359
HUWEL LIFESCIENCES: COMPANY OVERVIEW
FIGURE 1
POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SEGMENTATION & REGIONAL SCOPE
FIGURE 2
YEARS CONSIDERED
FIGURE 3
POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: RESEARCH DESIGN METHODOLOGY
FIGURE 5
BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY SIDE AND DEMAND SIDE PARTICIPANTS
FIGURE 6
BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
FIGURE 7
BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
FIGURE 8
CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
FIGURE 9
POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: TOP-DOWN APPROACH
FIGURE 10
DATA TRIANGULATION METHODOLOGY
FIGURE 11
POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: RESEARCH ASSUMPTIONS
FIGURE 12
POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2025 VS. 2030 (USD MILLION)
FIGURE 13
POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2025 VS. 2030 (USD MILLION)
FIGURE 14
POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2025 VS. 2030 (USD MILLION)
FIGURE 15
POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2025 VS. 2030 (USD MILLION)
FIGURE 16
POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)
FIGURE 17
POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2025 VS. 2030 (USD MILLION)
FIGURE 18
INCREASING ADVANCEMENTS IN MOLECULAR DIAGNOSTICS TECHNOLOGIES TO PROPEL MARKET
FIGURE 19
ASSAYS & KITS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
FIGURE 20
RT-PCR SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
FIGURE 21
OTHER SAMPLE TYPES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
FIGURE 22
RESPIRATORY DISEASES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
FIGURE 23
HOSPITALS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
FIGURE 24
ASIA PACIFIC REGION TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD
FIGURE 25
POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 26
PATENT ANALYSIS FOR POINT OF CARE MOLECULAR DIAGNOSTICS (JANUARY 2014–DECEMBER 2024)
FIGURE 27
VALUE CHAIN ANALYSIS OF POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: MAJOR VALUE ADDED DURING MANUFACTURING & ASSEMBLY PHASES
FIGURE 28
POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: SUPPLY CHAIN ANALYSIS
FIGURE 29
POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: ECOSYSTEM ANALYSIS
FIGURE 30
POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS
FIGURE 31
POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: TRENDS & DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
FIGURE 32
INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF POINT OF CARE MOLECULAR DIAGNOSTIC PRODUCTS
FIGURE 33
KEY BUYING CRITERIA FOR POINT OF CARE MOLECULAR DIAGNOSTIC PRODUCTS
FIGURE 34
NUMBER OF DEALS & FUNDING ACTIVITIES IN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET
FIGURE 35
MARKET POTENTIAL OF AI IN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET
FIGURE 36
NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SNAPSHOT
FIGURE 37
ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SNAPSHOT
FIGURE 38
REVENUE ANALYSIS OF KEY PLAYERS IN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, 2022–2024
FIGURE 39
MARKET SHARE ANALYSIS OF KEY PLAYERS IN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET (2024)
FIGURE 40
POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
FIGURE 41
POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: COMPANY FOOTPRINT
FIGURE 42
POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
FIGURE 43
EV/EBITDA OF KEY VENDORS
FIGURE 44
YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
FIGURE 45
POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: BRAND COMPARISON FOR INSTRUMENTS
FIGURE 46
DANAHER CORPORATION: COMPANY SNAPSHOT (2024)
FIGURE 47
BIOMÉRIEUX: COMPANY SNAPSHOT (2024)
FIGURE 48
F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2024)
FIGURE 49
ABBOTT: COMPANY SNAPSHOT (2024)
FIGURE 50
QIAGEN N.V.: COMPANY SNAPSHOT (2024)
FIGURE 51
QUIDELORTHO CORPORATION: COMPANY SNAPSHOT (2024)
FIGURE 52
CO-DIAGNOSTICS, INC.: COMPANY SNAPSHOT (2024)
FIGURE 53
BIOCARTIS: COMPANY SNAPSHOT (2022)
FIGURE 54
SD BIOSENSOR, INC.: COMPANY SNAPSHOT (2024)
FIGURE 55
GENEDRIVE PLC: COMPANY SNAPSHOT (2024)
Growth opportunities and latent adjacency in Point-of-Care Molecular Diagnostics Market